What is MRK's current stock price?

As of now, MRK is trading at $119.24, with a daily change of -0.06%.

What are the risks associated with MRK stock?

MRK has Low, risk level based on volatility, sector strength, volume, investor confidence and outlook.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

MRK Stock Analysis & IQ Rating | Merck Company

MRK

Merck Company

$119.24

-$0.07 | -0.06%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$122.66

MKT CAP

$295.96B

52W Low

$73.31

VOL

$10.38M

P/E Ratio

16.38

AVG VOL

$13.61M

RSI

66.60

TREND

Uptrend

MRK Stock IQ

Login to see Merck Company (MRK) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

MRK Target Price

Login to display

Strengths

MRK Rewards

Earnings are forecast to grow

MRK Rewards

Upgraded on attractively valued

MRK Rewards

Outperform the market

MRK Rewards

Trading below its fair value

Risk Analysis

MRK Risk Analysis

Investors losing their confidence

MRK Price Performance

$110.95 (+7.47%)

$92.86 (+28.41%)

$81.51 (+46.29%)

$93.15 (+28.01%)

1year

6month

3month

1month

MRK Analysts Opinion

Overall standing based on market and analyst consensus. menu Hover over the category for more information

MRK Analysts Opinion

MRK Analysts opinion is negative and has getting worse from the past 3 months

MRK Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

72%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

0%

29%

83%

MRK Street Sentiment

MRK Street Sentiment is bullish and have positive views on the near-term outlook

MRK Risk Level

MRK has Low risk level

Low

LOW

HIGH

MRK Performance Sentiment

Sentiments overview associated with events and the stock performance

72%

22%

Positive

Negative

57 out of 79
events present

17 out of 79
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support
Price

$119.31

Resistance
Price

$105.75

Current Price Range

$121.93

Show methods +

Analyst Consensus

Recent Upgrades and Downgrades

75%

Buy

Hold

Sell

Consensus Rating

BUY

6

2

0

Date

Action

Rating

Firm

Jan 20, 2026

Upgrade

Buy

BMO Capital

Jan 09, 2026

Upgrade

Outperform

Wolfe Research

Jan 08, 2026

Upgrade

Outperform

Wolfe Research

Dec 19, 2025

Upgrade

Outperform

BMO Capital

Dec 18, 2025

Price Target Raised

Outperform

BMO Capital

MRK Latest Analysis +

Sanofi replaces CEO Paul Hudson with outgoing Merck KGaA head. Outgoing Merck KGaA CEO Belén Garijo is set take the helm at Sanofi after the French vaccine specialist announced it would not renew existing CEO Paul Hudsons contract.The abrupt leadership change at Sanofi brings a close to a six-year tenure under Hudson. Sanofis board thanked him for

Today

$119.24 | -0.06%

Activity

Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction.

Today

$119.24 | -0.06%

Potential

Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant. French drugmaker Sanofi ousted CEO Paul Hudson on Thursday appointed Belén Garijo the head of German drugmaker Merck KGaA as new chief executive.

Today

$119.24 | -0.06%

Activity

Sanofi Pushes Out Paul Hudson in Sudden Leadership Change. Sanofis Chief Executive Officer Paul Hudson will be replaced by Merck KGaAs Belén Garijo after the French drugmaker decided not to renew his term.

Today

$119.24 | -0.06%

Activity

Mercks Keytruda Gets New FDA Approval For Expanded Use In Pretreated Ovarian Cancer Patients. The United States Food and Drug Administration (FDA) on Wednesday approved ) Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) plus paclitaxel with or without bevacizumab for previously treated .In September 2025 the FDA approved Keytruda Qlex.Wednesday’.s approval covers adults with PD-L1 platinum-resistant epithelial ovarian fallopian tube or primary perit

Wed Feb 11, 2026

$119.31 | +1.89%

Activity

Monday Sector Laggards: Healthcare Consumer Products. Looking at the sectors faring worst as of midday Monday shares of Healthcare companies are underperforming other sectors showing a 0.8% loss. Within that group Waters Corp. (Symbol: WAT) and Merck &. Co Inc (Symbol: MRK) are two of the days laggards showing a loss of 12.

Mon Feb 9, 2026

$117.65 | -3.47%

Momentum

Merck: The Spike Doesnt Make It Overvalued.

Mon Feb 9, 2026

$117.65 | -3.47%

Momentum

Potential

Mercks Subdued 2026 Outlook: What it Means After Q4 Results?. MRK posts conservative 2026 sales and EPS outlook given acquisition charges. Keytruda Animal Health and new drug launches are expected to drive 2026 growth.

Fri Feb 6, 2026

$121.93 | +1.82%

Activity

Jim Cramer on Merck & Co.: This Is One of My Favorite Pharmaceutical Stocks. Merck &. Co. Inc. (NYSE:MRK) is one of the stocks Jim Cramer looked at recently. Cramer discussed the companys latest quarter as he commented: This morning Merck reported a very solid quarter but gave what some people thought was a soft full-year forecast yet the stock finished up the session more than 2%. Why? Because [….]

Wed Feb 4, 2026

$118.33 | +2.15%

Earnings

Merck Reaches Analyst Target Price. In recent trading shares of Merck &. Co Inc (Symbol: MRK) have crossed above the average analyst 12-month target price of $115.12 changing hands for $115.84/share. When a stock reaches the target an analyst has set the analyst logically has two ways to react: downgrade on

Wed Feb 4, 2026

$118.33 | +2.15%

Potential

Rating

Runners Also Watch

Close Price

Change

SNY

Sanofi

47.03

-4.51%

PFE

Pfizer

27.47

-0.94%

AZN

Astrazeneca

204.52

-0.12%

ABBV

AbbVie

227.50

+2.99%

NVS

Novartis AG

161.18

+0.70%

FAQ About MRK Stock Insights

What is MRK current stock price?

What are MRK stock strengths?

What is MRK Risk Level?

What is MRK market cap and volume?

What is MRK current Stock IQ?

Should I buy MRK stock right now?

Is MRK a Strong Buy right now?

What does a 'Strong Buy' rating mean for MRK?

What does a 'Strong Sell' rating mean for MRK?

What factors influence MRK's Stock IQ?

Explore our MRK Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored MRK Stock Strategies
Effective Risk Management

FIND US ON

Receive our MRK Daily Alerts

Join over 5,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

MRK

Merck Company

Set Alerts

Current Price

$119.24

-$0.07 | -0.06%

52W High

$122.66

MKT CAP

$295.96B

52W Low

$73.31

VOL

$10.38M

P/E Ratio

16.38

AVG VOL

$13.61M

RSI

66.60

TREND

Uptrend

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Runners Also Watch

Symbol

Close

Change

SNY

Sanofi

47.03

-4.51%

PFE

Pfizer

27.47

-0.94%

AZN

Astrazeneca

204.52

-0.12%

ABBV

AbbVie

227.50

+2.99%

NVS

Novartis AG

161.18

+0.70%

MRK Price Performance

$110.95 (+7.47%)

$92.86 (+28.41%)

$81.51 (+46.29%)

$93.15 (+28.01%)

1year

6month

3month

1month

MRK Analysts Opinion

Overall standing per market and analyst expectations. menu Hover over the category for more information

MRK Analysts Opinion

MRK Analysts opinion is negative and has getting worse from the past 3 months

MRK Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

72%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

0%

29%

83%

MRK Street Sentiment

MRK Street Sentiment is bullish and have positive views on the near-term outlook

MRK Risk Level

MRK has Low risk level

Low

LOW

HIGH

MRK Performance Sentiment

Sentiments overview associated with events and the stock performance.

72%

22%

Positive

Negative

57 out of 79
events present

17 out of 79
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Key Price Levels

Average key support and resistance price levels

Support
Price

$119.31

Resistance
Price

$105.75

Current Price Range

$121.93

Show methods +

Latest Analyst Actions

Overall Wall Street Rating

75%

Buy

Hold

Sell

Consensus Rating

BUY

6

2

0

Date

Action

Rating

Firm

Jan 20, 2026

Upgrade

Buy

BMO Capital

Jan 09, 2026

Upgrade

Outperform

Wolfe Research

Jan 08, 2026

Upgrade

Outperform

Wolfe Research

Dec 19, 2025

Upgrade

Outperform

BMO Capital

Dec 18, 2025

Price Target Raised

Outperform

BMO Capital

MRK Stock IQ

Login to unlock Merck Company (MRK) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Target Price

Login to display

Stock Insights

Strengths

MRK Rewards

Earnings are forecast to grow

MRK Rewards

Upgraded on attractively valued

MRK Rewards

Outperform the market

MRK Rewards

Trading below its fair value

Risk Analysis

MRK Risk Analysis

Investors losing their confidence

MRK Latest Analysis

Sanofi replaces CEO Paul Hudson with outgoing Merck KGaA head. Outgoing Merck KGaA CEO Belén Garijo is set take the helm at Sanofi after the French vaccine specialist announced it would not renew existing CEO Paul Hudsons contract.The abrupt leadership change at Sanofi brings a close to a six-year tenure under Hudson. Sanofis board thanked him for

Today

$119.24 | -0.06%

Activity

Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction.

Today

$119.24 | -0.06%

Potential

Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant. French drugmaker Sanofi ousted CEO Paul Hudson on Thursday appointed Belén Garijo the head of German drugmaker Merck KGaA as new chief executive.

Today

$119.24 | -0.06%

Activity

Sanofi Pushes Out Paul Hudson in Sudden Leadership Change. Sanofis Chief Executive Officer Paul Hudson will be replaced by Merck KGaAs Belén Garijo after the French drugmaker decided not to renew his term.

Today

$119.24 | -0.06%

Activity

Mercks Keytruda Gets New FDA Approval For Expanded Use In Pretreated Ovarian Cancer Patients. The United States Food and Drug Administration (FDA) on Wednesday approved ) Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) plus paclitaxel with or without bevacizumab for previously treated .In September 2025 the FDA approved Keytruda Qlex.Wednesday’.s approval covers adults with PD-L1 platinum-resistant epithelial ovarian fallopian tube or primary perit

Wed Feb 11, 2026

$119.31 | +1.89%

Activity

Monday Sector Laggards: Healthcare Consumer Products. Looking at the sectors faring worst as of midday Monday shares of Healthcare companies are underperforming other sectors showing a 0.8% loss. Within that group Waters Corp. (Symbol: WAT) and Merck &. Co Inc (Symbol: MRK) are two of the days laggards showing a loss of 12.

Mon Feb 9, 2026

$117.65 | -3.47%

Momentum

Merck: The Spike Doesnt Make It Overvalued.

Mon Feb 9, 2026

$117.65 | -3.47%

Momentum

Potential

Discover MRK Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of MRK. We're here to help you make informed investment decisions today.

FIND US ON

Receive our MRK Daily Alerts

Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

MRK Stock trends

MRK Stock performance

MRK Stock analysis

MRK investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing MRK

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing MRK

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

MRK Stock Analysis & IQ Rating | Merck Company

MRK Stock IQ

MRK Target Price

MRK Analysts Opinion

MRK Street Sentiment

MRK Risk Level

MRK Performance Sentiment

Key Price Levels

Analyst Consensus

Explore our MRK Stock insights

Receive our MRK Daily Alerts

MRK Street Sentiment

MRK Risk Level

Key Price Levels

Latest Analyst Actions

Discover MRK Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of MRK. We're here to help you make informed investment decisions today.

Receive our MRK Daily Alerts

MRK Alerts